Core Insights - BioMed X and Novo Nordisk have initiated a collaboration focused on improving oral peptide drug delivery, addressing significant challenges in modern drug development [1][6] - The partnership aims to develop novel oral formulation technologies that enhance the bioavailability and retention of peptide drugs in the lower small intestine [6] Company Overview - BioMed X is an independent biomedical research institute located in Heidelberg, Germany, with additional sites in New Haven, Connecticut, and Ridgefield, Connecticut [7] - The institute operates at the intersection of academia and industry, focusing on biomedical research and drug discovery in various fields including oncology, immunology, and neuroscience [7][9] - Novo Nordisk, founded in 1923 and headquartered in Denmark, is a leading global healthcare company dedicated to combating chronic diseases, particularly diabetes, through scientific innovation [10]